.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Dr. Andrew Seidman Discusses the Management of Patients With Brain Metastases

Published on: June 2, 2013

Conference | ASCO: American Society of Clinical Oncology

Over the 20 years I've been treating breast cancer, I think this is the one area where we've really lagged behind in terms of making progress, said Andrew Seidman, MD, attending Physician, Memorial Sloan-Kettering Cancer Center, New York, NY.

“Over the 20 years I’ve been treating breast cancer, I think this is the one area where we've really lagged behind in terms of making progress,” said Andrew Seidman, MD, attending Physician, Memorial Sloan-Kettering Cancer Center, New York, NY.

Dr Seidman says that at the Annual Meeting of the American Society of Clinical Oncologists in Chicago, Aki Morikawa, MD, PhD, Memorial Sloan-Kettering Cancer Center, will present data on two commonly used breast cancer drugs, capecitabine and Lapatinib, to penetrate into breast cancer brain metastases. The observations found in the study should motivate further studies to examine the use of these agents.

This video was taken on May 31, 2013, at the ASCO Annual Meeting 2013 in Chicago, IL.